Maui Derm Conferences

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from Maui Derm NP+PA Fall 2024 in Nashville.

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

The ESS device, leveraging artificial intelligence, may allow for enhanced decision making among nurse practitioners as well as physician assistants evaluating patients for skin cancer.

These data from the DISCREET study highlight the impact of apremilast on men and women with genital psoriasis.

A handheld tool improved skin cancer detection in primary care, increasing diagnostic sensitivity to 96.3% compared to 83.9% without the device.

Del Rosso reviews several key highlights from his Maui Derm presentation on acne and rosacea updates from 2024.

This conference talk was titled Acute & Chronic Spontaneous Urticaria: Diagnostic and Therapeutic Strategies and presented a challenging case series to attendees.

Del Rosso highlights points from his conference talk on benzoyl peroxide (BPO) use among patients with acne and other updates.

This segment of her interview featured a conversation about the biggest takeaways and notable case series presented in Culton’s talk at Maui Derm NP+PA Fall.

This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.

In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

In her Maui Derm NP+PA Fall interview, Harper highlighted treatment approaches and unmet needs of patients with acne.

In her Maui Derm NP+PA Fall conference presentation, Baldwin highlighted the latest information on approaches to treating rosacea.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

This interview at the Fall 2024 Maui Derm conference features Melodie Young, with a discussion about updates in psoriasis and psoriatic arthritis therapy for children.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.